Frank M Biro1, Bin Huang2, Halley Wasserman3, Catherine M Gordon4, Susan M Pinney5. 1. Division of Adolescent and Transition Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic address: frank.biro@cchmc.org. 2. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Department of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 3. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 4. Division of Adolescent and Transition Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts. 5. Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Abstract
PURPOSE: Risk markers for breast cancer include earlier onset of menarche (age at menarche [AAM]) and peak height velocity (PHV). Insulin-like growth factor-1 (IGF-1) is associated with pubertal milestones, as well as cancer risk. This study examined the relationships between pubertal milestones associated with breast cancer risk and hormone changes in puberty. METHODS: This is a longitudinal study of pubertal maturation in 183 girls, recruited at ages 6-7, followed up between 2004 and 2018. Measures included age at onset of puberty, and adult height attained; PHV; AAM; adult height, and serum IGF-1, and estrone-to-androstenedione (E:A) ratio. RESULTS: PHV was greatest in early, and least in late maturing girls; length of the pubertal growth spurt was longest in early, and shortest in late maturing girls. Earlier AAM was related to greater PHV. IGF-1 concentrations tracked significantly during puberty; higher IGF-1 was related to earlier age of PHV, earlier AAM, greater PHV, and taller adult height. Greater E:A ratio was associated with earlier AAM. CONCLUSIONS: Factors driving the association of earlier menarche and pubertal growth with breast cancer risk may be explained through a unifying concept relating higher IGF-1 concentrations, greater lifelong estrogen exposure, and longer pubertal growth period, with an expanded pubertal window of susceptibility.
PURPOSE: Risk markers for breast cancer include earlier onset of menarche (age at menarche [AAM]) and peak height velocity (PHV). Insulin-like growth factor-1 (IGF-1) is associated with pubertal milestones, as well as cancer risk. This study examined the relationships between pubertal milestones associated with breast cancer risk and hormone changes in puberty. METHODS: This is a longitudinal study of pubertal maturation in 183 girls, recruited at ages 6-7, followed up between 2004 and 2018. Measures included age at onset of puberty, and adult height attained; PHV; AAM; adult height, and serum IGF-1, and estrone-to-androstenedione (E:A) ratio. RESULTS: PHV was greatest in early, and least in late maturing girls; length of the pubertal growth spurt was longest in early, and shortest in late maturing girls. Earlier AAM was related to greater PHV. IGF-1 concentrations tracked significantly during puberty; higher IGF-1 was related to earlier age of PHV, earlier AAM, greater PHV, and taller adult height. Greater E:A ratio was associated with earlier AAM. CONCLUSIONS: Factors driving the association of earlier menarche and pubertal growth with breast cancer risk may be explained through a unifying concept relating higher IGF-1 concentrations, greater lifelong estrogen exposure, and longer pubertal growth period, with an expanded pubertal window of susceptibility.
Authors: Frank M Biro; Susan M Pinney; Bin Huang; Erin R Baker; Donald Walt Chandler; Lorah D Dorn Journal: J Clin Endocrinol Metab Date: 2014-07-16 Impact factor: 5.958
Authors: Brian W Whitcomb; Alexandra Purdue-Smithe; Susan E Hankinson; JoAnn E Manson; Bernard A Rosner; Elizabeth R Bertone-Johnson Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958
Authors: Sarah V Ward; Anya Burton; Rulla M Tamimi; Ana Pereira; Maria Luisa Garmendia; Marina Pollan; Norman Boyd; Isabel Dos-Santos-Silva; Gertraud Maskarinec; Beatriz Perez-Gomez; Celine Vachon; Hui Miao; Martín Lajous; Ruy López-Ridaura; Kimberly Bertrand; Ava Kwong; Giske Ursin; Eunjung Lee; Huiyan Ma; Sarah Vinnicombe; Sue Moss; Steve Allen; Rose Ndumia; Sudhir Vinayak; Soo-Hwang Teo; Shivaani Mariapun; Beata Peplonska; Agnieszka Bukowska-Damska; Chisato Nagata; John Hopper; Graham Giles; Vahit Ozmen; Mustafa Erkin Aribal; Joachim Schüz; Carla H Van Gils; Johanna O P Wanders; Reza Sirous; Mehri Sirous; John Hipwell; Jisun Kim; Jong Won Lee; Caroline Dickens; Mikael Hartman; Kee-Seng Chia; Christopher Scott; Anna M Chiarelli; Linda Linton; Anath Arzee Flugelman; Dorria Salem; Rasha Kamal; Valerie McCormack; Jennifer Stone Journal: Breast Cancer Res Date: 2022-07-14 Impact factor: 8.408
Authors: Essi Syrjälä; Harri Niinikoski; Helena E Virtanen; Jorma Ilonen; Mikael Knip; Nina Hutri-Kähönen; Katja Pahkala; Olli T Raitakari; Wiwat Rodprasert; Jorma Toppari; Suvi M Virtanen; Riitta Veijola; Jaakko Peltonen; Jaakko Nevalainen Journal: PLoS One Date: 2021-11-18 Impact factor: 3.240
Authors: Robert A Hiatt; Susan L Stewart; Julianna Deardorff; Elizabeth Danial; Ekland Abdiwahab; Susan M Pinney; Susan L Teitelbaum; Gayle C Windham; Mary S Wolff; Lawrence H Kushi; Frank M Biro Journal: J Adolesc Health Date: 2021-07 Impact factor: 7.830